Tags

Type your tag names separated by a space and hit enter

In vitro models for the prediction of in vivo performance of oral dosage forms.
Eur J Pharm Sci. 2014 Jun 16; 57:342-66.EJ

Abstract

Accurate prediction of the in vivo biopharmaceutical performance of oral drug formulations is critical to efficient drug development. Traditionally, in vitro evaluation of oral drug formulations has focused on disintegration and dissolution testing for quality control (QC) purposes. The connection with in vivo biopharmaceutical performance has often been ignored. More recently, the switch to assessing drug products in a more biorelevant and mechanistic manner has advanced the understanding of drug formulation behavior. Notwithstanding this evolution, predicting the in vivo biopharmaceutical performance of formulations that rely on complex intraluminal processes (e.g. solubilization, supersaturation, precipitation…) remains extremely challenging. Concomitantly, the increasing demand for complex formulations to overcome low drug solubility or to control drug release rates urges the development of new in vitro tools. Development and optimizing innovative, predictive Oral Biopharmaceutical Tools is the main target of the OrBiTo project within the Innovative Medicines Initiative (IMI) framework. A combination of physico-chemical measurements, in vitro tests, in vivo methods, and physiology-based pharmacokinetic modeling is expected to create a unique knowledge platform, enabling the bottlenecks in drug development to be removed and the whole process of drug development to become more efficient. As part of the basis for the OrBiTo project, this review summarizes the current status of predictive in vitro assessment tools for formulation behavior. Both pharmacopoeia-listed apparatus and more advanced tools are discussed. Special attention is paid to major issues limiting the predictive power of traditional tools, including the simulation of dynamic changes in gastrointestinal conditions, the adequate reproduction of gastrointestinal motility, the simulation of supersaturation and precipitation, and the implementation of the solubility-permeability interplay. It is anticipated that the innovative in vitro biopharmaceutical tools arising from the OrBiTo project will lead to improved predictions for in vivo behavior of drug formulations in the GI tract.

Authors+Show Affiliations

Institute of Pharmaceutical Technology, Goethe University, Frankfurt/Main, Germany.Department of Global Medicines Development, AstraZeneca R&D, S-431 83 Mölndal, Sweden.Drug Product Development, Pharmaceutical Development and Manufacturing Sciences, Janssen Research and Development, Johnson & Johnson, Beerse, Belgium.Drug Delivery and Disposition, KU Leuven, Leuven, Belgium.Product Development, GlaxoSmithKline R&D, Harlow, United Kingdom.Department of Global Medicines Development, AstraZeneca R&D, S-431 83 Mölndal, Sweden.Clinical Pharmacology and Pharmacometrics, AstraZeneca R&D, Alderley Park, Macclesfield SK10 4TG, United Kingdom.Institute of Pharmaceutical Technology, Goethe University, Frankfurt/Main, Germany.Biologics and Pharmaceutical Science, H.Lundbeck A/S, Ottiliavej 9, DK 2500 Valby, Denmark.Biopharmaceutics and Pharmaceutical Technology, University of Greifswald, Greifswald, Germany.Development Laboratories, MSD, Hoddesdon, United Kingdom.Drug Product Design, Pfizer PGRD, Sandwich, Kent CT13 9NJ, United Kingdom.TNO, Zeist, The Netherlands.Material Science and Early Characterization, Research Center Aprath, Bayer Pharma AG, Germany.Pharmaceutical Design and Drug Delivery, University of Copenhagen, Denmark.TNO, Zeist, The Netherlands.Faculty of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis, 15771 Athens, Greece.Biopharmaceutics and Pharmaceutical Technology, University of Greifswald, Greifswald, Germany.Drug Delivery and Disposition, KU Leuven, Leuven, Belgium. Electronic address: patrick.augustijns@pharm.kuleuven.be.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

23988843

Citation

Kostewicz, Edmund S., et al. "In Vitro Models for the Prediction of in Vivo Performance of Oral Dosage Forms." European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, vol. 57, 2014, pp. 342-66.
Kostewicz ES, Abrahamsson B, Brewster M, et al. In vitro models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci. 2014;57:342-66.
Kostewicz, E. S., Abrahamsson, B., Brewster, M., Brouwers, J., Butler, J., Carlert, S., Dickinson, P. A., Dressman, J., Holm, R., Klein, S., Mann, J., McAllister, M., Minekus, M., Muenster, U., Müllertz, A., Verwei, M., Vertzoni, M., Weitschies, W., & Augustijns, P. (2014). In vitro models for the prediction of in vivo performance of oral dosage forms. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, 57, 342-66. https://doi.org/10.1016/j.ejps.2013.08.024
Kostewicz ES, et al. In Vitro Models for the Prediction of in Vivo Performance of Oral Dosage Forms. Eur J Pharm Sci. 2014 Jun 16;57:342-66. PubMed PMID: 23988843.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vitro models for the prediction of in vivo performance of oral dosage forms. AU - Kostewicz,Edmund S, AU - Abrahamsson,Bertil, AU - Brewster,Marcus, AU - Brouwers,Joachim, AU - Butler,James, AU - Carlert,Sara, AU - Dickinson,Paul A, AU - Dressman,Jennifer, AU - Holm,René, AU - Klein,Sandra, AU - Mann,James, AU - McAllister,Mark, AU - Minekus,Mans, AU - Muenster,Uwe, AU - Müllertz,Anette, AU - Verwei,Miriam, AU - Vertzoni,Maria, AU - Weitschies,Werner, AU - Augustijns,Patrick, Y1 - 2013/08/27/ PY - 2013/05/13/received PY - 2013/08/07/revised PY - 2013/08/13/accepted PY - 2013/8/31/entrez PY - 2013/8/31/pubmed PY - 2014/12/17/medline KW - Biorelevant KW - In vitro evaluation KW - In vivo biopharmaceutical performance KW - Innovative Medicines Initiative (IMI) KW - Oral Biopharmaceutical Tools (OrBiTo) KW - Oral drug formulations SP - 342 EP - 66 JF - European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences JO - Eur J Pharm Sci VL - 57 N2 - Accurate prediction of the in vivo biopharmaceutical performance of oral drug formulations is critical to efficient drug development. Traditionally, in vitro evaluation of oral drug formulations has focused on disintegration and dissolution testing for quality control (QC) purposes. The connection with in vivo biopharmaceutical performance has often been ignored. More recently, the switch to assessing drug products in a more biorelevant and mechanistic manner has advanced the understanding of drug formulation behavior. Notwithstanding this evolution, predicting the in vivo biopharmaceutical performance of formulations that rely on complex intraluminal processes (e.g. solubilization, supersaturation, precipitation…) remains extremely challenging. Concomitantly, the increasing demand for complex formulations to overcome low drug solubility or to control drug release rates urges the development of new in vitro tools. Development and optimizing innovative, predictive Oral Biopharmaceutical Tools is the main target of the OrBiTo project within the Innovative Medicines Initiative (IMI) framework. A combination of physico-chemical measurements, in vitro tests, in vivo methods, and physiology-based pharmacokinetic modeling is expected to create a unique knowledge platform, enabling the bottlenecks in drug development to be removed and the whole process of drug development to become more efficient. As part of the basis for the OrBiTo project, this review summarizes the current status of predictive in vitro assessment tools for formulation behavior. Both pharmacopoeia-listed apparatus and more advanced tools are discussed. Special attention is paid to major issues limiting the predictive power of traditional tools, including the simulation of dynamic changes in gastrointestinal conditions, the adequate reproduction of gastrointestinal motility, the simulation of supersaturation and precipitation, and the implementation of the solubility-permeability interplay. It is anticipated that the innovative in vitro biopharmaceutical tools arising from the OrBiTo project will lead to improved predictions for in vivo behavior of drug formulations in the GI tract. SN - 1879-0720 UR - https://www.unboundmedicine.com/medline/citation/23988843/In_vitro_models_for_the_prediction_of_in_vivo_performance_of_oral_dosage_forms_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0928-0987(13)00338-2 DB - PRIME DP - Unbound Medicine ER -